214 related articles for article (PubMed ID: 26449981)
1. Parental smoke exposure and the development of nicotine craving in adolescent novice smokers: the roles of DRD2, DRD4, and OPRM1 genotypes.
Kleinjan M; Engels RC; DiFranza JR
BMC Pulm Med; 2015 Oct; 15():115. PubMed ID: 26449981
[TBL] [Abstract][Full Text] [Related]
2. Initial responses to the first dose of nicotine in novel smokers: the role of exposure to environmental smoking and genetic predisposition.
Schuck K; Otten R; Engels RC; Kleinjan M
Psychol Health; 2014; 29(6):698-716. PubMed ID: 24446757
[TBL] [Abstract][Full Text] [Related]
3. Genetic Variation of the Mu Opioid Receptor (OPRM1) and Dopamine D2 Receptor (DRD2) is Related to Smoking Differences in Patients with Schizophrenia but not Bipolar Disorder.
Hirasawa-Fujita M; Bly MJ; Ellingrod VL; Dalack GW; Domino EF
Clin Schizophr Relat Psychoses; 2017; 11(1):39-48. PubMed ID: 28548579
[TBL] [Abstract][Full Text] [Related]
4. Gene and gene by sex associations with initial sensitivity to nicotine in nonsmokers.
Perkins KA; Lerman C; Coddington S; Jetton C; Karelitz JL; Wilson A; Jennings JR; Ferrell R; Bergen AW; Benowitz NL
Behav Pharmacol; 2008 Sep; 19(5-6):630-40. PubMed ID: 18690117
[TBL] [Abstract][Full Text] [Related]
5. Dopamine receptor genes (DRD2, DRD3 and DRD4) and gene-gene interactions associated with smoking-related behaviors.
Vandenbergh DJ; O'Connor RJ; Grant MD; Jefferson AL; Vogler GP; Strasser AA; Kozlowski LT
Addict Biol; 2007 Mar; 12(1):106-16. PubMed ID: 17407504
[TBL] [Abstract][Full Text] [Related]
6. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
[TBL] [Abstract][Full Text] [Related]
7. Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood.
Perkins KA; Lerman C; Grottenthaler A; Ciccocioppo MM; Milanak M; Conklin CA; Bergen AW; Benowitz NL
Behav Pharmacol; 2008 Sep; 19(5-6):641-9. PubMed ID: 18690118
[TBL] [Abstract][Full Text] [Related]
8. Association analyses for dopamine receptor gene polymorphisms and weight status in a longitudinal analysis in obese children before and after lifestyle intervention.
Roth CL; Hinney A; Schur EA; Elfers CT; Reinehr T
BMC Pediatr; 2013 Nov; 13():197. PubMed ID: 24283216
[TBL] [Abstract][Full Text] [Related]
9. Lack of association of DRD4 exon 3 VNTR genotype with reactivity to dynamic smoking cues in movies.
Lochbuehler K; Verhagen M; Munafò MR; Engels RC
Drug Alcohol Depend; 2013 Sep; 132(1-2):324-8. PubMed ID: 23522492
[TBL] [Abstract][Full Text] [Related]
10. DRD4 and DRD2 genes, parenting, and adolescent delinquency: Longitudinal evidence for a gene by environment interaction.
Chhangur RR; Overbeek G; Verhagen M; Weeland J; Matthys W; Engels RC
J Abnorm Psychol; 2015 Nov; 124(4):791-802. PubMed ID: 26595468
[TBL] [Abstract][Full Text] [Related]
11. Influence of the A118G Polymorphism of the OPRM1 Gene and Exon 3 VNTR Polymorphism of the DRD4 Gene on Cigarette Craving After Alcohol Administration.
Lechner WV; Knopik VS; McGeary JE; Spillane NS; Tidey JW; McKee SA; Metrik J; Leventhal AM; Rohsenow DJ; Kahler CW
Nicotine Tob Res; 2016 May; 18(5):632-6. PubMed ID: 26092968
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation in dopamine pathways differentially associated with smoking progression in adolescence.
Laucht M; Becker K; Frank J; Schmidt MH; Esser G; Treutlein J; Skowronek MH; Schumann G
J Am Acad Child Adolesc Psychiatry; 2008 Jun; 47(6):673-681. PubMed ID: 18434921
[TBL] [Abstract][Full Text] [Related]
13. DRD4 VNTR polymorphism is associated with transient fMRI-BOLD responses to smoking cues.
McClernon FJ; Hutchison KE; Rose JE; Kozink RV
Psychopharmacology (Berl); 2007 Nov; 194(4):433-41. PubMed ID: 17611740
[TBL] [Abstract][Full Text] [Related]
14. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.
Lerman C; Jepson C; Wileyto EP; Epstein LH; Rukstalis M; Patterson F; Kaufmann V; Restine S; Hawk L; Niaura R; Berrettini W
Neuropsychopharmacology; 2006 Jan; 31(1):231-42. PubMed ID: 16123753
[TBL] [Abstract][Full Text] [Related]
15. DRD2/ANKK1 TaqI polymorphism and smoking behavior of Egyptian male cigarette smokers.
Radwan GN; El-Setouhy M; Mohamed MK; Hamid MA; Azem SA; Kamel O; Israel E; Loffredo CA
Nicotine Tob Res; 2007 Dec; 9(12):1325-9. PubMed ID: 18058350
[TBL] [Abstract][Full Text] [Related]
16. Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?
David SP; Niaura R; Papandonatos GD; Shadel WG; Burkholder GJ; Britt DM; Day A; Stumpff J; Hutchison K; Murphy M; Johnstone E; Griffiths SE; Walton RT
Nicotine Tob Res; 2003 Dec; 5(6):935-42. PubMed ID: 14668077
[TBL] [Abstract][Full Text] [Related]
17. Effects of dopamine D2 receptor (DRD2) and transporter (SLC6A3) polymorphisms on smoking cue-induced cigarette craving among African-American smokers.
Erblich J; Lerman C; Self DW; Diaz GA; Bovbjerg DH
Mol Psychiatry; 2005 Apr; 10(4):407-14. PubMed ID: 15381926
[TBL] [Abstract][Full Text] [Related]
18. Lack of association between DRD2 Taq1A gene polymorphism and smoking cessation therapy: a meta-analysis.
Choi HD; Shin WG
Int J Clin Pharmacol Ther; 2015 Jun; 53(6):415-21. PubMed ID: 25881752
[TBL] [Abstract][Full Text] [Related]
19. The DRD4 VNTR polymorphism influences reactivity to smoking cues.
Hutchison KE; LaChance H; Niaura R; Bryan A; Smolen A
J Abnorm Psychol; 2002 Feb; 111(1):134-43. PubMed ID: 11866166
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic genetic variation moderates the effect of nicotine on cigarette reward.
Harrell PT; Lin HY; Park JY; Blank MD; Drobes DJ; Evans DE
Psychopharmacology (Berl); 2016 Jan; 233(2):351-60. PubMed ID: 26497691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
